Nicole So, Sara Monaghan, Katelynn Davis, Grant Bullock, Wendy Shallenberger, Ahmad Al-Attar
The objective of this 12-color/13-antibody single-tube panel is to assist in the diagnosis of T/NK-cell leukemias and lymphomas. In the clinical setting, the absence of a standardized T/NK-cell panel limits inter-laboratory data comparability, contributes to diagnostic variability, and results in redundant efforts across laboratories to design and validate panels for flow cytometry. Developing and promoting a panel that allows for rapid and fairly comprehensive labeling of surface T/NK-cell markers, including the anti-T-cell receptor β-chain constant region 1 (TRBC1) antibody, will streamline the workflow by establishing a standard immunophenotyping T/NK-cell panel for detecting neoplastic T/NK cells and lay the foundation for future COMIPs.
{"title":"COMIP-001: A clinical 13-antibody, 12-color flow cytometry panel for optimized immunophenotyping of T/NK cells in human leukemia and lymphoma diagnostics.","authors":"Nicole So, Sara Monaghan, Katelynn Davis, Grant Bullock, Wendy Shallenberger, Ahmad Al-Attar","doi":"10.1002/cytob.70015","DOIUrl":"https://doi.org/10.1002/cytob.70015","url":null,"abstract":"<p><p>The objective of this 12-color/13-antibody single-tube panel is to assist in the diagnosis of T/NK-cell leukemias and lymphomas. In the clinical setting, the absence of a standardized T/NK-cell panel limits inter-laboratory data comparability, contributes to diagnostic variability, and results in redundant efforts across laboratories to design and validate panels for flow cytometry. Developing and promoting a panel that allows for rapid and fairly comprehensive labeling of surface T/NK-cell markers, including the anti-T-cell receptor β-chain constant region 1 (TRBC1) antibody, will streamline the workflow by establishing a standard immunophenotyping T/NK-cell panel for detecting neoplastic T/NK cells and lay the foundation for future COMIPs.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>[Color figure can be viewed at wileyonlinelibrary.com]</p><p>This issue of Clinical Cytometry B deals with several topics which are relevant in either the hematology and oncology discipline, mostly focusing on multiple myeloma and malignant lymphoma. Two of these studies reported data on standardization of flow cytometry methods which may be of great value in several clinical situations. It is a personal pleasure to comment here on these interesting manuscripts.</p><p>The first paper of this issue was written by Deutsch-Biedermann et al. (<span>2026</span>); it was related to the development of a one-tube flow cytometry panel for measurable residual disease (MRD) detection in multiple myeloma patients (MM). Recent data has clearly demonstrated that the achievement of MRD negativity after first-line therapy for MM is one of the strongest surrogate markers for both overall survival and progression-free survival and is now widely used as an endpoint in several clinical trials (Anderson et al., <span>2021</span>; Mateos et al., <span>2019</span>; Munshi et al., <span>2020</span>). It is also known that flow cytometry represents the leading technique for MRD status assessment in MM and related diseases (Devitt et al., <span>2025</span>). Furthermore, compliance with the International Myeloma working group (IMWG) Next Generation Flow (NGF) criteria for MRD negativity requires the absence of immunophenotypically abnormal and clonal plasma cells with a minimum sensitivity of 1 in 10<sup>5</sup> nucleated cells in bone marrow aspirates using the EuroFlow standard method or a validated equivalent method. Interestingly, in this manuscript, authors have proposed a novel MRD panel based on the use of all EuroFlow recommended immunophenotypic markers (cytoplasmic light chain kappa and lambda, CD19, CD27, CD38, CD45, CD56, CD81, CD117, CD138) other than the CD200 marker, which allows the inclusion of a total of 11 fluorochromes in one tube (Terra et al., <span>2025</span>). This protocol meets the quality specifications of the IMWG. This flow cytometry protocol showed higher sensitivity than the previously developed flow panel and showed concordant results with the EuroFlow NGF panel, thus sustaining the reliability and sensitivity of this approach for detecting MRD in MM patients.</p><p>In the paper by Groves et al. (<span>2026</span>) the authors provide guidance for performing minor modifications to validated antibody panels designed to ensure consistent and accurate results in the immunophenotyping of hematopoietic cells in several diseases. However, it is well known that in unforeseen situations, such as unique or unusual immunophenotypes or supply chain issues, ad hoc modifications to these panels are strongly necessary (D'Addio et al., <span>2025</span>; Kelleher et al., <span>2024</span>; Lanza et al., <span>2025</span>; Terra et al., <span>2025</span>; Tian et al., <span>2024</span>). This manuscript provides guidance for performing minor modificati
{"title":"Issue Highlights—January 2026","authors":"Francesco Lanza","doi":"10.1002/cytob.70007","DOIUrl":"10.1002/cytob.70007","url":null,"abstract":"<p>[Color figure can be viewed at wileyonlinelibrary.com]</p><p>This issue of Clinical Cytometry B deals with several topics which are relevant in either the hematology and oncology discipline, mostly focusing on multiple myeloma and malignant lymphoma. Two of these studies reported data on standardization of flow cytometry methods which may be of great value in several clinical situations. It is a personal pleasure to comment here on these interesting manuscripts.</p><p>The first paper of this issue was written by Deutsch-Biedermann et al. (<span>2026</span>); it was related to the development of a one-tube flow cytometry panel for measurable residual disease (MRD) detection in multiple myeloma patients (MM). Recent data has clearly demonstrated that the achievement of MRD negativity after first-line therapy for MM is one of the strongest surrogate markers for both overall survival and progression-free survival and is now widely used as an endpoint in several clinical trials (Anderson et al., <span>2021</span>; Mateos et al., <span>2019</span>; Munshi et al., <span>2020</span>). It is also known that flow cytometry represents the leading technique for MRD status assessment in MM and related diseases (Devitt et al., <span>2025</span>). Furthermore, compliance with the International Myeloma working group (IMWG) Next Generation Flow (NGF) criteria for MRD negativity requires the absence of immunophenotypically abnormal and clonal plasma cells with a minimum sensitivity of 1 in 10<sup>5</sup> nucleated cells in bone marrow aspirates using the EuroFlow standard method or a validated equivalent method. Interestingly, in this manuscript, authors have proposed a novel MRD panel based on the use of all EuroFlow recommended immunophenotypic markers (cytoplasmic light chain kappa and lambda, CD19, CD27, CD38, CD45, CD56, CD81, CD117, CD138) other than the CD200 marker, which allows the inclusion of a total of 11 fluorochromes in one tube (Terra et al., <span>2025</span>). This protocol meets the quality specifications of the IMWG. This flow cytometry protocol showed higher sensitivity than the previously developed flow panel and showed concordant results with the EuroFlow NGF panel, thus sustaining the reliability and sensitivity of this approach for detecting MRD in MM patients.</p><p>In the paper by Groves et al. (<span>2026</span>) the authors provide guidance for performing minor modifications to validated antibody panels designed to ensure consistent and accurate results in the immunophenotyping of hematopoietic cells in several diseases. However, it is well known that in unforeseen situations, such as unique or unusual immunophenotypes or supply chain issues, ad hoc modifications to these panels are strongly necessary (D'Addio et al., <span>2025</span>; Kelleher et al., <span>2024</span>; Lanza et al., <span>2025</span>; Terra et al., <span>2025</span>; Tian et al., <span>2024</span>). This manuscript provides guidance for performing minor modificati","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 1","pages":"7-10"},"PeriodicalIF":2.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cytob.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"\"What are we measuring?\" reconsidering the biological identity and clinical interpretation of malaria-derived particles.","authors":"Zhihao Lei","doi":"10.1002/cytob.70011","DOIUrl":"https://doi.org/10.1002/cytob.70011","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alice Yue, Ryan R Brinkman, Veronica Nash, Fabian Junker, Goce Bogdanoski, Anagha Divekar, Aaron Tyznik, Josef Spidlen, Wolfgang Kern, Jordi Petriz, Kaska Wloka, Kamila Czechowska
{"title":"Response to \"Bridging the implementation gap in AI-assisted flow cytometry\".","authors":"Alice Yue, Ryan R Brinkman, Veronica Nash, Fabian Junker, Goce Bogdanoski, Anagha Divekar, Aaron Tyznik, Josef Spidlen, Wolfgang Kern, Jordi Petriz, Kaska Wloka, Kamila Czechowska","doi":"10.1002/cytob.70009","DOIUrl":"https://doi.org/10.1002/cytob.70009","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Quantifying malarial parasite density is crucial for diagnosis and treatment in endemic areas. While Malaria-derived particles (MDPs) have been linked to malaria pathology, a direct quantification method for routine laboratory use remains unestablished. To address this, our study optimized a flow cytometry approach to enumerate MDPs per microliter of blood. Specimens were incubated with propidium iodide and red blood cell (RBC) lysis solution. The number of MDPs was quantified using a CytoFlex flow cytometer, size-standard beads, and counting beads. Electron microscopy was used to study the ultrastructures of the malarial parasites in the lysed RBC specimens. A significant increase in MDP levels was detected in blood samples from P. falciparum and P. vivax infections, but fewer than 1 particle/μL of MDPs were detected in the controls. The number of MDPs correlated with the percentage of infected red blood cells (iRBCs) obtained by manual counting (R2 = 0.94). The dilution assay demonstrated a strong correlation between the measured and expected values of the MDPs. An electron microscopic study demonstrated that different stages of malarial parasites exist in lysed RBCs in the form of membrane-bound spherical cells. A positive association was established between parasite density and MDPs across both P. falciparum (R2 = 0.94) and P. vivax (R2 = 0.91) infections. We demonstrated the potential use of flow cytometry for determining the MDP concentration. The developed approach is reliable and straightforward for the diagnosis and treatment of patients with malarial parasite infection in routine laboratory settings.
{"title":"A novel flow cytometry approach to quantify malaria-derived particles.","authors":"Attakorn Palasuwan, Kritsamon Sophondilok, Sumate Ampawong, Suttipat Srisutham, Egarit Noulsri, Duangdao Palasuwan","doi":"10.1002/cytob.70006","DOIUrl":"https://doi.org/10.1002/cytob.70006","url":null,"abstract":"<p><p>Quantifying malarial parasite density is crucial for diagnosis and treatment in endemic areas. While Malaria-derived particles (MDPs) have been linked to malaria pathology, a direct quantification method for routine laboratory use remains unestablished. To address this, our study optimized a flow cytometry approach to enumerate MDPs per microliter of blood. Specimens were incubated with propidium iodide and red blood cell (RBC) lysis solution. The number of MDPs was quantified using a CytoFlex flow cytometer, size-standard beads, and counting beads. Electron microscopy was used to study the ultrastructures of the malarial parasites in the lysed RBC specimens. A significant increase in MDP levels was detected in blood samples from P. falciparum and P. vivax infections, but fewer than 1 particle/μL of MDPs were detected in the controls. The number of MDPs correlated with the percentage of infected red blood cells (iRBCs) obtained by manual counting (R<sup>2</sup> = 0.94). The dilution assay demonstrated a strong correlation between the measured and expected values of the MDPs. An electron microscopic study demonstrated that different stages of malarial parasites exist in lysed RBCs in the form of membrane-bound spherical cells. A positive association was established between parasite density and MDPs across both P. falciparum (R<sup>2</sup> = 0.94) and P. vivax (R<sup>2</sup> = 0.91) infections. We demonstrated the potential use of flow cytometry for determining the MDP concentration. The developed approach is reliable and straightforward for the diagnosis and treatment of patients with malarial parasite infection in routine laboratory settings.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-17DOI: 10.1002/cyto.b.22267
Devasis Panda, Narender Tejwani, Sabina Langer
{"title":"Coexistent dual CD4+/CD8- and CD4-/CD8+ T-cell large granular lymphocytic leukemia in a young adult male: An exceedingly rare finding.","authors":"Devasis Panda, Narender Tejwani, Sabina Langer","doi":"10.1002/cyto.b.22267","DOIUrl":"10.1002/cyto.b.22267","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"57-59"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vandana Panakkal, Raniah Al Amri, Stacey Mamatas, Sara A Monaghan, Ahmad Al-Attar
{"title":"Authors' Response to Letter from Khanolkar and Ahmed concerning our article \"An unusual pattern observed upon the addition of CD79b to a flow cytometry B-cell lymphoma panel\" (Panakkal et al., 2025). Cytometry Part B: Clinical Cytometry. DOI: 10.1002/cyto.b.22246. PMID: 40657818.","authors":"Vandana Panakkal, Raniah Al Amri, Stacey Mamatas, Sara A Monaghan, Ahmad Al-Attar","doi":"10.1002/cytob.70005","DOIUrl":"https://doi.org/10.1002/cytob.70005","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antibody titration is essential for optimizing platelet flow cytometry, a technique widely used to evaluate platelet phenotype, activation status, and function. This manuscript outlines practical approaches for platelet antibody titration in whole blood, with tailored strategies for constitutive and inducible markers. It emphasizes the use of appropriate controls, consideration of marker coexpression, and selection of subsaturating antibody concentrations to maximize signal resolution while minimizing background and artifactual activation. Quantitative metrics such as the stain index and separation index are introduced as tools for evaluating staining performance. The discussion also addresses key technical variables, including combinatorial titration, spillover spreading, lot variability, and antibody-induced activation. Titration under final assay conditions is recommended to ensure reproducibility and biological relevance. These strategies provide a foundation for developing robust, high-resolution platelet assays that support both research and clinical applications, particularly as flow cytometry evolves toward greater automation and standardization.
{"title":"Signal without noise: Practical antibody titration for platelet flow cytometry.","authors":"Benjamin E J Spurgeon","doi":"10.1002/cytob.70004","DOIUrl":"https://doi.org/10.1002/cytob.70004","url":null,"abstract":"<p><p>Antibody titration is essential for optimizing platelet flow cytometry, a technique widely used to evaluate platelet phenotype, activation status, and function. This manuscript outlines practical approaches for platelet antibody titration in whole blood, with tailored strategies for constitutive and inducible markers. It emphasizes the use of appropriate controls, consideration of marker coexpression, and selection of subsaturating antibody concentrations to maximize signal resolution while minimizing background and artifactual activation. Quantitative metrics such as the stain index and separation index are introduced as tools for evaluating staining performance. The discussion also addresses key technical variables, including combinatorial titration, spillover spreading, lot variability, and antibody-induced activation. Titration under final assay conditions is recommended to ensure reproducibility and biological relevance. These strategies provide a foundation for developing robust, high-resolution platelet assays that support both research and clinical applications, particularly as flow cytometry evolves toward greater automation and standardization.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang
{"title":"Challenges and approaches in the diagnosis and differential diagnosis of atypical CLL: A response to 'Defining atypical CLL for reproducible diagnosis: Implications of the work by Wang et al.'","authors":"Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang","doi":"10.1002/cytob.70003","DOIUrl":"https://doi.org/10.1002/cytob.70003","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号